Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

Gudmundsdotter Lindvi; Nilsson Charlotta; Brave Andreas; Hejdeman Bo; Earl Patricia; Moss Bernard; Robb Merlin; Cox Josephine; Michael Nelson; Marovich Mary; Biberfeld Gunnel; Sandstrom Eric; Wahren Britta

首页> 外文期刊>Vaccine >Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

【24h】

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

机译：尽管已有牛痘免疫力，但重组修饰的安卡拉牛痘疫苗（MVA）可有效增强人类DNA引发的HIV特异性免疫反应

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but: did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.

机译：载体特异性免疫反应的存在可能会阻碍对载体编码的外源抗原的反应的诱导。我们评估了现有的针对牛痘病毒的免疫力对健康志愿者使用HIV-1 DNAprime-MVA增强疫苗免疫后诱导HIV特异性反应的影响。在用HIV-1 DNA质粒进行了3次初免免疫后，通过单次注射编码HIV-1蛋白的重组MVA加强了志愿者的免疫力。预先存在的针对牛痘病毒的免疫力并未降低对HIV-1作出反应的个体比例，但是：确实降低了反应程度。我们的结果表明，基于牛痘的载体可用于有效诱导对载体化HIV-1抗原的免疫反应，即使是在已对牛痘病毒具有免疫力的个体中也是如此。

著录项

来源
《Vaccine》 |2009年第33期|共7页
作者
Gudmundsdotter Lindvi; Nilsson Charlotta; Brave Andreas; Hejdeman Bo; Earl Patricia; Moss Bernard; Robb Merlin; Cox Josephine; Michael Nelson; Marovich Mary; Biberfeld Gunnel; Sandstrom Eric; Wahren Britta;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词
HIV-1 vaccine; Modified Vaccinia virus Ankara (MVA); Pre-existing immunity;

机译：HIV-1疫苗;改良的痘苗病毒安卡拉（MVA）;已有的免疫力;

相似文献

外文文献
中文文献
专利

1. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity [J] . Gudmundsdotter Lindvi, Nilsson Charlotta, Brave Andreas, Vaccine . 2009,第33期

机译：尽管已有牛痘免疫力，但重组修饰的安卡拉牛痘疫苗（MVA）可有效增强人类DNA引发的HIV特异性免疫反应
2. Enhanced CD8(+) T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cell [J] . Gomez CE, Rodriguez D, Rodriguez JR, Vaccine . 2001,第5a6期

机译：用纯化的融合蛋白和修饰的牛痘病毒安卡拉（MVA-TAB）重组疫苗引发后，针对HIV-1 Env的V3环多表位多肽（TAB13）的增强的CD8（+）T细胞免疫应答：体液和病毒的比较细胞
3. Broad and Potent Cellular and Humoral Immune Responses After a Second Late HIV-Modified Vaccinia Virus Ankara Vaccination in HIV-DNA-Primed and HIV-Modified Vaccinia Virus Ankara-Boosted Swedish Vaccinees [J] . Charlotta Nilsson, Karina Godoy-Ramirez, Bo Hejdeman, AIDS Research and Human Retroviruses . 2014,第3期

机译：在艾滋病毒-DNA灌注和艾滋病毒改性痘苗病毒Ankara-Boosted瑞典疫苗中，在第二次艾滋病毒改性的痘苗病病毒Ankara接种后的广泛和有效的细胞和体液免疫反应
4. IMMUNE RESPONSE FOR THE OPEN READING FRAME 2 (ORF2) MEMBRANE GLYCOPROTEIN OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) DELIVERED IN PIGS BY RECOMBINANT VACCINIA VIRUS [C] . D. Rogan, J. Levere, D. Yoo Congress of the International Pig Veterinary Society . 2000

机译：通过重组疫苗病毒，猪生殖和呼吸综合征病毒（PRRSV）的猪生殖和呼吸综合征病毒（PRRSV）的免疫应答血液
5. Comparison of murine B7-1 and B7-2 in generating an anti-tumor immune response when delivered by recombinant vaccinia virus vaccination. [D] . Beckerleg, Anne Marie Sabrina. 2002

机译：当通过重组牛痘病毒疫苗接种时，鼠B7-1和B7-2在产生抗肿瘤免疫应答中的比较。
6. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity [O] . Lindvi Gudmundsdotter, Charlotta Nilsson, Andreas Brave, -1

机译：尽管预先存在的痘苗病度重组改性痘苗病毒Ankara（MVA）有效地提高了人类的DNA引发的艾滋病毒特异性免疫应答
7. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. [O] . Mwau, M, Cebere, I, Sutton, J, 2004

机译：人类免疫缺陷病毒1（HIV-1）进化枝A疫苗正在临床试验中：通过DNA和重组修饰的痘苗病毒安卡拉（MVA）疫苗刺激人的HIV特异性T细胞反应。
8. Evaluation of the Efficacy of Modified Vaccinia Ankara (MVA)/IMVAMUNE (registered trademark) Against Aerosolized Rabbitpox Virus in a Rabbit Model [R] . Garza, N. L., Hatkin, J. M., Livingston, V., 2009

机译：改良痘苗剂安卡拉（mVa）/ ImVamUNE（注册商标）对兔模型气雾化兔痘病毒的疗效评价

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

摘要

著录项

相似文献

相关主题

期刊订阅